Metabolic Tumor Volume Predicts Outcome in Follicular Lymphoma

Share this content:
Baseline total metabolic tumor volume is associated with treatment outcomes for patients with high-tumor-burden follicular lymphoma.
Baseline total metabolic tumor volume is associated with treatment outcomes for patients with high-tumor-burden follicular lymphoma.

Baseline total metabolic tumor volume (TMTV) is associated with treatment outcomes for patients with high-tumor-burden follicular lymphoma, according to a study published in the Journal of Clinical Oncology.1

It is difficult to identify patients at high risk of progression and early mortality using current prognostic models. Researchers assessed the prognostic impact of TMTV measured at baseline with [18F]fluorodeoxyglucose/positron emission tomography-computed tomography ([18F]FDG/PET-CT) scans among patients with follicular lymphoma.

Investigators conducted a pooled analysis using data from 185 patients with follicular lymphoma who received immunochemotherapy as part of 3 prospective clinical trials. Of those, 92% had stage III to IV disease, 37% had a Follicular Lymphoma International Prognostic Index (FLIPI) score of 3 to 5, and 31% had a FLIPI2 score of 3 to 5.

Median follow-up was 64 months; overall 5-year progression-free survival and overall survival were 55% and 92%, respectively.

The 29% of patients with TMTV at baseline greater than 510 cm3 had substantially reduced survival [hazard ratio [HR] for 5-year overall survival, 3.45; P = .010). These patients also had a nearly 3-fold higher risk of progression at 5 years (HR, 2.90; P < .001).

RELATED: Baseline Metabolic Tumor Volume Predicts Prognosis of Follicular Lymphoma

After adjusting for confounding factors, TMTV (HR, 2.3; P = .002) and FLIPI2 score (HR, 2.2; P = .002) were independent predictors of progression-free survival. In combination with FLIPI2 score, TMTV identifies patients at high risk of disease progression.                 

Reference

  1. Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high–tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016 Aug 22. doi: 10.1200/JCO.2016.66.9440 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters